Revtorpyk (gedatolisib) coverage: breast cancer approval and billing

The landscape of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer is experiencing a significant diagnostic and therapeutic shift. On July 14, 2026, the FDA approved Revtorpyk (gedatolisib, Celcuity Inc.), marking a milestone as the first therapy specifically indicated for patients without a PIK3CA mutation (PIK3CA wild-type). This post-approval guide follows our earlier gedatolisib PDUFA preview; the verified label, dosing, and billing details here replace the pre-approval projections.

For oncology clinics, buy-and-bill teams, and commercial payers, the approval of Revtorpyk introduces immediate operational challenges and strategic decisions. As a newly approved intravenous oncology drug, Revtorpyk enters the market with a "J-code gap"—a period of several months during which no product-specific billing code exists. Access teams must navigate interim billing using unclassified codes while pre-positioning diagnostic testing workflows. Furthermore, payers must determine how this pan-PI3K/mTOR inhibitor fits alongside established therapies like Piqray (alpelisib), which target mutation-specific subpopulations within the same therapeutic line.

This guide provides a comprehensive analysis of Revtorpyk’s clinical data, the interim billing pathway for buy-and-bill teams, its commercial positioning against alpelisib, and the prior authorization criteria expected from commercial plans.

---

Short answer

An oncology clinic's buy-and-bill team preparing for a patient eligible for Revtorpyk (gedatolisib) must evaluate several critical operational and clinical factors:

• Indication: FDA-approved on July 14, 2026, for adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation detected (wild-type), whose disease progressed on or after at least one endocrine therapy line in the metastatic setting. It is administered in combination with fulvestrant, with or without palbociclib (Ibrance).
• Dosing: Administered as a 180 mg intravenous infusion over 30 minutes once weekly on Days 1, 8, and 15 of a 28-day cycle.
• Interim Billing: Because it was newly approved, there is no permanent product-specific J-code. Providers must bill using the interim unclassified antineoplastic code J9999 (or miscellaneous code C9399 for hospital outpatient settings) until CMS assigns a permanent HCPCS code, expected on October 1, 2026, or January 1, 2027.
• Cost and Launch: Commercial launch is scheduled for late Q3 2026, with a pre-launch Expanded Access Program (EAP) available. Celcuity has not disclosed the Wholesale Acquisition Cost (WAC), but Wall Street analysts estimate pricing will fall between $24,000 and $28,000 per month ($288,000 to $336,000 annually), representing a premium over existing oral therapies.
• Biomarker Split: Revtorpyk serves the PIK3CA wild-type population (~60% of HR+/HER2- patients), while alpelisib (Piqray) is restricted to PIK3CA-mutated disease (~40% of patients). Celcuity plans to file a supplemental NDA (sNDA) in Q3 2026 to expand Revtorpyk's label into PIK3CA-mutated disease, which will set up direct competition between the two drugs.

---

What did the FDA approve Revtorpyk (gedatolisib) for on July 14, 2026?

The FDA approval of Revtorpyk on July 14, 2026, is based on the results of the phase 3 VIKTORIA-1 trial (NCT05501886). The study evaluated gedatolisib in patients with HR+/HER2- locally advanced or metastatic breast cancer whose disease progressed during or after treatment with a CDK4/6 inhibitor combined with endocrine therapy.

The VIKTORIA-1 Trial Design and Efficacy Data

VIKTORIA-1 was a randomized, open-label, multi-center trial that enrolled patients who were documented to be PIK3CA wild-type (meaning no mutation was detected in the PIK3CA gene via companion diagnostic testing). Patients were randomized into three primary treatment arms:

• Arm A (n=131): Gedatolisib 180 mg IV (Days 1, 8, 15 of a 28-day cycle) + fulvestrant 500 mg IM (Day 1 and Day 15 of Cycle 1, then Day 1 of subsequent cycles) + palbociclib 125 mg orally once daily (Days 1 to 21 of a 28-day cycle).
• Arm B (n=130): Gedatolisib 180 mg IV + fulvestrant 500 mg IM (without the CDK4/6 inhibitor).
• Arm C (n=131): Fulvestrant 500 mg IM monotherapy (the active control).

The primary endpoint of the trial was progression-free survival (PFS) in the PIK3CA wild-type cohort, evaluated by blinded independent central review (BICR). The efficacy readouts demonstrated a significant benefit for gedatolisib-based regimens:

The data showed a 76% reduction in the risk of disease progression or death for patients receiving the triple-combination regimen (Arm A) compared to fulvestrant monotherapy, and a 67% reduction for the double-combination regimen (Arm B). The median PFS of 9.3 months in the triple-combination arm is clinically significant for a patient population that has progressed on prior CDK4/6 inhibitor therapy, where endocrine monotherapy historically yields poor outcomes (reflected in the 2.0-month median PFS of Arm C).

Mechanism of Action: Dual PI3K/mTOR Inhibition

Gedatolisib is a highly potent, intravenous pan-PI3K and mTOR inhibitor. Unlike selective inhibitors, gedatolisib targets all four class I isoforms of phosphoinositide 3-kinase (PI3K-α, PI3K-β, PI3K-γ, and PI3K-delta) as well as the mammalian target of rapamycin (mTOR) complexes 1 and 2 (mTORC1 and mTORC2).

In HR+/HER2- breast cancer, hyperactivation of the PI3K/AKT/mTOR signaling pathway is a primary mechanism of resistance to endocrine therapies. By simultaneously blocking all PI3K isoforms and both mTOR complexes, gedatolisib shuts down this survival pathway more completely than selective agents, preventing the compensatory feedback loops that often lead to drug resistance.

---

Fulvestrant and Palbociclib Combination Partners

Understanding the administration parameters of Revtorpyk requires examining its FDA-approved combination partners. The drug is approved to be given alongside fulvestrant, with or without palbociclib.

Fulvestrant (Faslodex)

Fulvestrant is a Selective Estrogen Receptor Degrader (SERD) that binds competitively to estrogen receptors on breast cancer cells, causing them to degrade. This downregulates estrogen receptor signaling, which is a major driver of cell growth in HR+ breast cancer.

• Dosing and Route: Fulvestrant is administered as two 250 mg intramuscular (IM) injections (one in each buttock) for a total dose of 500 mg.
• Schedule: The standard regimen requires loading doses on Days 1, 15, and 29, followed by once-monthly maintenance doses (every 28 days) thereafter.
• Payer Considerations: Since fulvestrant is a mature, multi-source generic, its cost to the plan is low. However, because it is an intramuscular injection administered by a nurse, it incurs minor provider administration fees under the medical benefit.

Palbociclib (Ibrance)

Palbociclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are activated by binding to D-cyclins, leading to the phosphorylation of retinoblastoma (Rb) protein, which promotes cell cycle progression from G1 to S phase.

• Dosing and Route: Dosed as a 125 mg capsule or tablet taken orally once daily.
• Schedule: Administered on a 21-days-on, 7-days-off cycle (28 days total).
• Payer Considerations: Palbociclib is a high-cost oral brand specialty drug that routes through the pharmacy benefit. Payers typically require prior authorization for palbociclib. The addition of gedatolisib to the palbociclib + fulvestrant doublet creates a high-cost triple therapy, which will draw close review from P&T committees.

---

Intracellular Mechanisms: Overcoming CDK4/6 and Endocrine Resistance

To understand why Revtorpyk's PFS results (9.3 months vs. 2.0 months) are clinically meaningful, one must examine the intracellular pathways that drive breast cancer resistance.

                  [Endocrine Therapy]
                           ↓
             [Blocks Estrogen Receptor (ER)]
                           ↓
        [Cancer Cell Upregulates Bypass Pathway]
                           ↓
              [PI3K / AKT / mTOR Pathway]
                           ↓
      [Upregulates Cyclin D1 & Activates CDK4/6]
                           ↓
               [Cell Cycle Progression]
                           ↓
              [RESTORING SENSITIVITY via]
            [Dual PI3K/mTOR (Gedatolisib)]
                           +
              [CDK4/6 Blockade (Palbociclib)]

The Estrogen Receptor and PI3K Intersect

Estrogen receptor (ER) signaling and the PI3K/AKT/mTOR pathway are cross-regulated. When endocrine therapy blocks ER signaling, breast cancer cells adapt by upregulating the PI3K/AKT/mTOR pathway. This pathway stimulates cell growth and survival independently of estrogen.

Furthermore, active PI3K signaling upregulates cyclin D1 expression, which binds and activates CDK4/6, driving the cell cycle forward even in the presence of CDK4/6 inhibitors. This crosstalk explains why patients eventually develop resistance to first-line CDK4/6 inhibitor regimens (such as Ibrance + Letrozole).

Re-establishing Pathway Blockade

By introducing gedatolisib, clinicians can block both the upstream PI3K signaling and downstream mTOR complexes. When combined with the CDK4/6 inhibitor palbociclib and the estrogen receptor degrader fulvestrant, the tumor cell's escape routes are simultaneously blocked.

The VIKTORIA-1 trial proved that this combination is highly effective, showing that adding gedatolisib to fulvestrant and palbociclib (Arm A) extended median PFS to 9.3 months, compared to 7.4 months for gedatolisib + fulvestrant (Arm B) and only 2.0 months for fulvestrant alone (Arm C).

---

How do providers bill gedatolisib before a permanent J-code is assigned?

Because Revtorpyk is administered intravenously, it is managed under the medical benefit through a "buy-and-bill" model rather than the pharmacy benefit. Under buy-and-bill, the oncology clinic purchases the drug from a specialty distributor, administers it to the patient, and bills the patient's insurance.

The J-Code Gap and Financial Risk

Newly approved intravenous drugs do not have a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) code (commonly referred to as a J-code) at launch, as we describe in our J-code timing and interim billing risk framework. CMS updates the J-code registry quarterly. For a drug approved on July 14, 2026, the earliest a permanent J-code can be assigned is October 1, 2026, or January 1, 2027.

During this J-code gap, clinics must bill using unclassified or miscellaneous codes. This introduces significant financial risk for the practice:

1. Manual Claim Reviews: Claims billed with unclassified codes cannot be processed automatically by insurance systems. They require manual review by the payer, which can delay reimbursement by 60 to 90 days.
2. Reimbursement Denials: If the clinic fails to submit the required supporting documentation, the claim will be denied, leaving the clinic responsible for the cost of the drug. Given the estimated monthly price of $24,000 to $28,000, a single denied claim represents a substantial financial loss for a practice.

Interim Billing Best Practices

To minimize the risk of delays and denials during the J-code gap, oncology billing teams should implement the following procedures:

• Use the Correct Miscellaneous HCPCS Codes:
  • J9999: Not otherwise classified, antineoplastic drugs (standard for physician-office clinics).
  • J3590: Unclassified biologics (used if the payer's policy specifically requires it, though gedatolisib is a small molecule).
  • C9399: Unclassified drugs or biologicals (mandatory for hospital outpatient departments billing under the Medicare Outpatient Prospective Payment System).
• Provide Detailed NDC Information: Every claim must include the National Drug Code (NDC) in the 5-4-2 format. The NDC must be entered in the correct loop and segment of the electronic 837P or 837I claim form.
• Specify the Dose and Units Administered: The unclassified claim must clearly state the exact dose administered (180 mg) and the number of vials used. In the description field of the claim (Box 19 on the paper CMS-1500 form or the electronic equivalent), enter: "Revtorpyk (gedatolisib) 180 mg IV infusion, administered on [Date], NDC [Number], Boxed Quantity [Number]."
• Attach the Commercial Invoice: Most payers require a copy of the purchase invoice to verify the acquisition cost of the drug before they will approve payment under an unclassified code.
• Obtain Prior Authorization with the Interim Code: Access teams must secure prior authorization before administering the drug. The authorization letter must explicitly list the interim HCPCS code (e.g., J9999) alongside the drug name to prevent automatic denials during claims processing.

---

How does gedatolisib position against alpelisib (Piqray) given the PIK3CA biomarker split?

The commercial and clinical positioning of Revtorpyk is defined by its relationship with Piqray (alpelisib, Novartis), which was approved in May 2019. Other biomarkers partition the broader HR+/HER2- population — for example, Veppanu (vepdegestrant) targets ESR1-mutated disease — but Revtorpyk's access story turns specifically on the PIK3CA wild-type vs mutated split. Payers evaluate all of these drugs when designing breast cancer formularies.

The Biomarker Split: Wild-Type vs. Mutated

The primary differentiator between the two therapies is the patient's biomarker status:

• Piqray (alpelisib) is approved only for PIK3CA-mutated disease. In the SOLAR-1 trial, alpelisib combined with fulvestrant showed a median PFS benefit only in patients whose tumors harbored a PIK3CA mutation (11.0 months vs. 5.7 months for placebo). In the PIK3CA wild-type cohort, alpelisib did not show a statistically significant benefit, and it is not FDA-approved for these patients.
• Revtorpyk (gedatolisib) is approved for PIK3CA wild-type disease. Its initial approval target is the approximately 60% of HR+/HER2- metastatic breast cancer patients who do not have a PIK3CA mutation. This provides these patients with a targeted therapy option where endocrine monotherapy was previously the clinical standard.

Expanded Label Strategy (sNDA Pipeline)

While the initial FDA approval of Revtorpyk is limited to the PIK3CA wild-type population, Celcuity is pursuing a strategy to expand its market share. The company has announced plans to submit a supplemental New Drug Application (sNDA) to the FDA in Q3 2026.

This sNDA will seek approval for gedatolisib in patients with PIK3CA-mutated HR+/HER2- metastatic breast cancer, supported by data from the PIK3CA-mutated cohort of the VIKTORIA-1 trial. If approved, gedatolisib will compete directly with Piqray across the entire HR+/HER2- second-line breast cancer population, regardless of mutation status.

Tolerability and Safety Profiles

The safety profile of Revtorpyk is a key factor for payers and clinical teams, particularly when comparing its pan-PI3K/mTOR inhibition to Piqray's alpha-specific inhibition:

• Hyperglycemia: Piqray’s alpha-selective inhibition directly affects insulin signaling, leading to high rates of severe, grade 3/4 hyperglycemia (approximately 36% in clinical trials) that often requires insulin therapy or leads to discontinuation. While Revtorpyk also causes hyperglycemia due to its pan-PI3K/mTOR blockade, clinical data suggests its rate of severe hyperglycemia is lower and more manageable, though it still requires baseline monitoring.
• Stomatitis (Mouth Sores): Because Revtorpyk inhibits the mTOR pathway (similar to Afinitor/everolimus), stomatitis is a common adverse event. The prescribing information recommends prophylactic treatment with dexamethasone oral solution to reduce the incidence and severity of mouth sores.
• Dermatologic Reactions: Rashes and dry skin are common to both drug classes.
• Infusion Reactions: Because Revtorpyk is an intravenous drug, patients may experience mild-to-moderate infusion-related reactions, requiring pre-medication (antihistamines and corticosteroids) and clinical monitoring during administration.

---

Clinical Safety and Management of Adverse Events

Because gedatolisib blocks both PI3K and mTOR pathways, managing adverse events is essential for maintaining treatment adherence. Access teams and clinicians must prepare for specific toxicity management protocols:

1. Stomatitis and Mucositis

Stomatitis is a class effect of mTOR inhibitors. In the VIKTORIA-1 trial, stomatitis occurred in a significant proportion of patients in the gedatolisib arms.

• Prophylaxis: Clinicians are advised to initiate a prophylactic dexamethasone 0.5 mg/5 mL oral solution rinse (swish and spit for 2 minutes, 4 times daily) starting on Day 1 of Cycle 1 and continuing for the first 8 weeks of therapy.
• Management: Grade 1/2 stomatitis is managed with dose holds and topical treatments. Grade 3 stomatitis (painful ulcerations interfering with oral intake) requires holding gedatolisib until symptoms resolve to $\le$ Grade 1, followed by a dose reduction.

2. Hyperglycemia

PI3K pathway inhibition blocks glucose uptake in skeletal muscle and adipose tissue, leading to insulin resistance and secondary hyperglycemia.

• Monitoring: Fasting blood glucose and HbA1c must be checked at baseline, weekly for the first 6 weeks of treatment, and monthly thereafter.
• Management: For fasting glucose $> 160$ to $250$ mg/dL (Grade 2), clinicians should initiate oral hypoglycemic therapy (e.g., metformin). For glucose $> 250$ mg/dL (Grade 3), gedatolisib must be held until levels fall below $160$ mg/dL, and reinitiated at a reduced dose.

3. Diarrhea and Gastrointestinal Toxicity

Mild-to-moderate diarrhea is common. Patients should be instructed to keep over-the-counter loperamide on hand and start it at the first sign of loose stools. For persistent Grade 2 or 3 diarrhea, the dose of gedatolisib must be held until symptoms resolve.

---

Biomarker Testing: Diagnostic Routing and Payer Policy

Since Revtorpyk is indicated only for PIK3CA wild-type patients, documenting the absence of a mutation is a prerequisite for insurance coverage.

Testing Modalities

Clinicians can use two primary methods to determine PIK3CA status:

1. Tissue Biopsy (Next-Generation Sequencing - NGS): Tissue from the primary tumor or a metastatic lesion is analyzed. While tissue biopsy is the clinical gold standard, it requires an invasive procedure, and historical samples may not reflect the current mutational state of metastatic disease.
2. Liquid Biopsy (Cell-Free DNA - cfDNA): A blood sample is analyzed for circulating tumor DNA (ctDNA). Liquid biopsy is non-invasive and provides rapid results. However, due to potential false negatives (if the tumor is not shedding DNA into the blood), a negative liquid biopsy result should be confirmed with a tissue biopsy if feasible.

Payer Criteria for Companion Diagnostics

P&T committees require companion diagnostic documentation before approving Revtorpyk — a common friction point, as we detail in our analysis of biomarker documentation mismatches in oncology prior authorization. Access teams must submit the formal pathology or NGS report from an approved diagnostic platform (such as FoundationOne CDx or Guardant360 CDx). Payers will verify that the report lists the patient's status as "PIK3CA mutation NOT detected" or "PIK3CA wild-type" before authorizing treatment.

---

What will Revtorpyk cost and when does it launch commercially?

As of mid-July 2026, Celcuity has not published the official Wholesale Acquisition Cost (WAC) for Revtorpyk. The drug is scheduled for commercial launch in late Q3 2026.

Commercial Value and Price Projections

Oncology market analysts project that Celcuity will price Revtorpyk at a premium to reflect its position as a targeted therapy for a historically underserved population.

• Citizens Bank Analyst Projection: Establishes a target WAC of $28,000 per month.
• BioWorld and Industry Benchmarks: Project a price range of $24,000 to $26,000 per month.

An annual cost of $288,000 to $336,000 places Revtorpyk at a higher price tier than oral options like Piqray (which has a WAC of approximately $18,000 to $20,000 per month). Payers will justify this premium based on the PFS benefit demonstrated in the VIKTORIA-1 trial, but will use strict prior authorization criteria to manage utilization.

The Expanded Access Program (EAP)

To support patients during the transition between FDA approval and commercial availability, Celcuity is running an Expanded Access Program (EAP). This program allows eligible patients to receive gedatolisib free of charge before the late Q3 2026 launch.

Buy-and-bill clinics can use the EAP to start appropriate patients on therapy without facing immediate reimbursement risk under unclassified codes.

---

What prior-authorization criteria should access teams expect?

To manage utilization of this high-cost oncology therapy, commercial plans (e.g., CVS Health, UnitedHealthcare, Anthem) are expected to implement strict prior authorization policies.

Prior Authorization Requirements:
1. Diagnosis: HR+/HER2- locally advanced or metastatic breast cancer
2. Biomarker: Documented absence of PIK3CA mutation (wild-type status)
3. Step Therapy: Progression on or after >= 1 prior line of endocrine therapy
4. Combinations: Prescribed in combination with fulvestrant (+/- palbociclib)
5. Exclusions: No active interstitial lung disease, pneumonitis, or severe hyperglycemia (HbA1c >= 8.0%)

Key Prior Authorization Requirements

1. Documented PIK3CA Wild-Type Status: Payers will require a pathology report or genetic test result (using next-generation sequencing or an FDA-approved companion diagnostic) confirming the absence of a mutation in the PIK3CA gene. Claims submitted without this documentation will be denied.
2. Prior Endocrine Therapy Failure: Patients must have progressed on or after at least one endocrine therapy regimen (e.g., an aromatase inhibitor like letrozole or anastrozole, or tamoxifen) in the metastatic setting. Payers will allow and expect prior exposure to CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib), consistent with the population enrolled in the VIKTORIA-1 trial.
3. Approved Combination Partner: The prior authorization request must specify that Revtorpyk will be administered in combination with fulvestrant, with or without palbociclib. Monotherapy requests will not be approved.
4. Clinical Baseline Requirements: Payers may require documentation of baseline laboratory values, including:
   • Fasting blood glucose $< 140$ mg/dL or HbA1c $< 8.0%$ to manage hyperglycemia risk.
   • Adequate renal and hepatic function.
   • Confirmation that the patient does not have active pneumonitis or interstitial lung disease (ILD), which are warnings on the drug's label.

Reauthorization and Renewal Criteria

Reauthorization will typically be granted every 6 months, subject to documentation of:

• Clinical Benefit: No evidence of disease progression as determined by imaging (CT/PET scans or MRI).
• Tolerability: Absence of severe, unmanageable grade 3/4 toxicities (such as refractory stomatitis, uncontrolled hyperglycemia, or severe dermatologic reactions) that would require discontinuation.

---

FAQ

Is there a permanent J-code for Revtorpyk (gedatolisib)?

No. As of its July 14, 2026 approval, there is no permanent J-code. A product-specific J-code is expected in a future CMS quarterly update (likely October 1, 2026, or January 1, 2027). Until then, providers must use unclassified codes like J9999 or C9399.

Does Revtorpyk work in PIK3CA-mutated breast cancer, or only wild-type?

The initial FDA approval is limited to PIK3CA wild-type disease. However, Celcuity has evaluated gedatolisib in PIK3CA-mutated cohorts during the VIKTORIA-1 trial and plans to submit a supplemental NDA (sNDA) in Q3 2026 to expand the label to include mutated cases.

What is the dosing schedule for gedatolisib (Revtorpyk)?

Revtorpyk is administered as a 180 mg intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28-day cycle. It is given in combination with fulvestrant (and optionally palbociclib), which follows its own standard dosing schedule.

When will Revtorpyk be commercially available, and is there an expanded access program?

Commercial launch is expected in late Q3 2026. Patients can access the drug before launch through Celcuity's Expanded Access Program (EAP), which provides gedatolisib free of charge to eligible patients.

---

Sources

1. FDA Approval Notice: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. July 14, 2026. FDA Approved Drugs.
2. Celcuity Press Release: Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for HR+/HER2- Metastatic Breast Cancer. July 14, 2026. Celcuity Investor Relations.
3. ClinicalTrials.gov Record: A Study of Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (VIKTORIA-1). NCT05501886. ClinicalTrials.gov VIKTORIA-1.
4. CMS HCPCS Code Guidelines: HCPCS Level II Application Summary and Coding Update Cycles. CMS HCPCS Level II.
5. NCCN Clinical Guidelines: NCCN Clinical Practice Guidelines in Oncology — Breast Cancer. NCCN Breast Cancer Guidelines.